Table 2 Description of the cohort
From: A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases
Total (n = 84) No. (%) | |
|---|---|
Age, years (mean ± SD) (min–max) | 49.8 ± 18.70 (18–94) |
Age > 65 years old | 19 (22.9) |
Gender (male) | 34 (40.46) |
Type of disease | |
Myopathy | 27 (40.5) |
Neuropathy | 23 (27.4) |
Myasthenia | 34 (40.5) |
Origin of the disease | |
Acquired | 44 (53.0) |
Genetic | 39 (47.0) |
Severity of neuromuscular diseaseƗ | |
Low | 30 (36.6) |
Moderate | 36 (43.9) |
High | 16 (19.5) |
Mobility | |
Walk | 58 (70.7) |
Walk with help | 12 (14.6) |
Wheelchair | 12 (14.6) |
Comorbidities | |
Heart failure | 16 (20.3) |
Respiratory failure | 28 (35.9) |
Hypertension | 11 (13.1) |
Diabetes | 10 (11.9) |
Obesity | 8 (9.5) |
Medication‡ | |
Corticosteroids | 14 (16.7) |
Other immunosuppressants | 17 (20.2) |
Diagnosis of COVID-19 | |
PCR | 24 (28.6) |
Thoracic CT-Scan | 4 (4.8) |
PCR + Thoracic CT-Scan | 20 (23.8) |
Neither § | 36 (42.8) |
Effect of COVID-19 | |
Without | 48 (57.8) |
Aggravating factor | 26 (31.3) |
Death | 9 (10.8) |
Severity of COVID-19 | |
Low | 48 (57.8) |
Moderate | 23 (27.7) |
High | 12 (14.5) |
Medical care | |
Medical unit | 23 (27.7) |
Intensive care unit | 12 (14.5) |
Home care | 48 (57.8) |